Infectious Diseases Society of America 2023 guidance on the treatment of antimicrobial resistant gram-negative infections.
Open accessThe DOI matches its Crossref record; 695 of the 697 references it cites were found in a registry or an index.
Abstract
Background: The Infectious Diseases Society of America is committed to providing up-to-date guidance on the treatment of antimicrobial-resistant infections. This guidance document focuses on infections caused by extended-spectrum β-lactamase–producing Enterobacterales, AmpC β-lactamase-producing Enterobacterales, carbapenem-resistant Enterobacterales, Pseudomonas aeruginosa with difficult-to-treat resistance, carbapenem-resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia. This updated document replaces previous versions of the guidance document. Methods: A panel of 6 infectious diseases specialists with expertise in managing antimicrobial-resistant infections formulated questions about the treatment of infections caused by extended-spectrum β-lactamase-producing Enterobacterales, AmpC β-lactamase-producing Enterobacterales, carbapenem-resistant Enterobacterales, Pseudomonas aeruginosa with difficult-to-treat resistance, carbapenem-resistant Acinetobacter baumannii, and S. maltophilia. Because of differences in the epidemiology of resistance and availability of specific anti-infectives internationally, this document focuses on the treatment of infections in the United States. Results: Preferred and alternative suggested treatment approaches are provided with accompanying rationales, assuming the causative organism has been identified and antibiotic susceptibility results are known. Approaches to empiric treatment, transitioning to oral therapy, duration of therapy, and other management considerations are also discussed briefly. Suggested approaches apply for both adult and pediatric populations, although suggested antibiotic dosages are provided only for adults. Conclusions: The field of antimicrobial-resistance is highly dynamic. Consultation with an infectious diseases specialist is recommended for the treatment of antimicrobial resistant infections. This document is current as of 31 December 2022 and will be updated periodically. The most current version of this document, including date of publication, is available at www.idsociety.org/practice-guideline/amr-guidance/.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis
Murray, C. J. L., Ikuta, K. S., Sharara, F., Swetschinski, L., Robles Aguilar, G., Gray, A., Han, C., Bisignano, C., Rao, P., Wool, E., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(21)02724-0 · Cited by 16,316
Magiorakos, A.-P., Srinivasan, A., Carey, R. B., Carmeli, Y., Falagas, M. E., Giske, C. G., Harbarth, S., Hindler, J. F., Kahlmeter, G., Olsson-Liljequist, B., et al. (2012) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2011.03570.x · Cited by 14,449
Antibiotic resistance threats in the United States, 2019
(U.S.), C. F. D. C. A. P. (2019) · doi:10.15620/cdc:82532 · Cited by 5,782
Kalil, A. C., Metersky, M. L., Klompas, M., Muscedere, J., Sweeney, D. A., Palmer, L. B., Napolitano, L. M., O'Grady, N. P., Bartlett, J. G., Carratalà, J., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw353 · Cited by 3,892
Naghavi, M., Vollset, S. E., Ikuta, K. S., Swetschinski, L. R., Gray, A. P., Wool, E. E., Robles Aguilar, G., Mestrovic, T., Smith, G., Han, C., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01867-1 · Cited by 3,791
Gupta, K., Hooton, T. M., Naber, K. G., Wullt, B., Colgan, R., Miller, L. G., Moran, G. J., Nicolle, L. E., Raz, R., Schaeffer, A. J., et al. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/ciq257 · Cited by 3,038
Updated Functional Classification of β-Lactamases
Bush, K., & Jacoby, G. A. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01009-09 · Cited by 2,367
Jacoby, G. A. (2009) · Clinical Microbiology Reviews · doi:10.1128/cmr.00036-08 · Cited by 2,165
Lister, P. D., Wolter, D. J., & Hanson, N. D. (2009) · Clinical Microbiology Reviews · doi:10.1128/cmr.00040-09 · Cited by 1,789
Stenotrophomonas maltophilia: an Emerging Global Opportunistic Pathogen
Brooke, J. S. (2012) · Clinical Microbiology Reviews · doi:10.1128/cmr.00019-11 · Cited by 1,434
Research works printed but not linked: 10
- Clinical and Laboratory Standards Institute, 2023, M100: performance standards for antimicrobial susceptibility testing
- Sharara, 2019, Is piperacillin-tazobactam effective for the treatment of pyelonephritis caused by ESBL-producing organisms?, Clin Infect Dis, 71
- Centers for Disease Control and Prevention, 2015, Facility guidance for control of carbapenem-resistant Enterobacteriaceae (CRE): November 2015 update—CRE toolkit
- Chen, 2022, Efficacy and safety of ceftazidime-avibactam for the treatment of carbapenem-resistant enterobacterales bloodstream infection: a systematic review and meta-analysis, Microbiol Spectr, 10
- Shields, 2017, Emergence of ceftazidime-avibactam resistance due to plasmid-borne blaKPC-3 mutations during treatment of carbapenem-resistant Klebsiella pneumoniae infections, Antimicrob Agents Chemother, 61
- Li, 2022, Increased expression and amplification of blaKPC-2 contributes to resistance to ceftazidime/avibactam in a sequence type 11 carbapenem-resistant Klebsiella pneumoniae strain, Microbiol Spectr, 10
- Morrissey, 2020, In vitro activity of eravacycline against gram-negative bacilli isolated in clinical laboratories worldwide from 2013 to 2017, Antimicrob Agents Chemother, 64
- Karlowsky, 2020, In vitro activity of imipenem/relebactam and ceftolozane/tazobactam against clinical isolates of gram-negative bacilli with difficult-to-treat resistance and multidrug-resistant phenotypes—SMART United States 2015–2017, Clin Infect Dis, 72
- Skoglund, 2018, In vivo resistance to ceftolozane/tazobactam in Pseudomonas aeruginosa arising by AmpC- and non-AmpC-mediated pathways, Case Rep Infect Dis, 2018
- Cheah, 2015, New pharmacokinetic/pharmacodynamic studies of systemically administered colistin against Pseudomonas aeruginosa and Acinetobacter baumannii in mouse thigh and lung infection models: smaller response in lung infection, J Antimicrob Chemother, 70, 3291
Cited by
Items 601–700 of 808
Alvarado, L. R. M., Landayan, A. M., Williams, K. N., Frederick, C. M., Zhang, Z., & Gauthier, T. P. (2024) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkae135
Antibiotic Use in the Surgical Intensive Care Unit
Laquian, L. F. P., & Efron, P. A. (2024) · Advances in Surgery · doi:10.1016/j.yasu.2024.04.012
Mandarić, A., Šitum, I., Siroglavić, M., Lovrić, D., Karmelić, D., Erceg, A., Mažar, M., & Mihaljević, S. (2024) · Medicina Fluminensis · doi:10.21860/medflum2024_316208 · Cited by 1
Hydross, M. V., Samad, S. A., Savitri, M. B., & Upadhyay, A. D. (2024) · Motaleat-e Tatbiqi-e Honar · doi:10.61186/jommid.12.1.50
“Establishing an optimal regimen for treating multidrug-resistant Gram-negative infections in critically ill patients requires further research to address the inconsistencies in recommended dosing frequencies for colistin administration across guidelines [6-8].”
BackgroundShoulders, B. R., Santevecchi, B. A., Venugopalan, V., & Alexander, K. M. (2024) · Surgical Infections · doi:10.1089/sur.2024.135
Citrobacter Causing Septic Arthritis: A Case Report
Levine, K. K., Dahl, M., Tauseef, A., & Thirumalareddy, J. (2024) · Infectious Diseases & Immunity · doi:10.1097/id9.0000000000000127
Drug utilization evaluation of ceftazidime-avibactam in a tertiary care hospital
Tejaswini, V., Sri, M. H., Samreen, S. M., Brundasree, C., & Archana, J. (2024) · International Journal of Community Medicine and Public Health · doi:10.18203/2394-6040.ijcmph20242175
Tehaili, H., Saleh, R., & Malviya, M. (2024) · Infectious Diseases in Clinical Practice · doi:10.1097/ipc.0000000000001398
Guerra, A. D., Volk, C. F., Peterson-Weber, A., Peters, J. M., Sakoulas, G., Sauer, J., & Rose, W. E. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.09.27.615437
Enfeksiyon Hastalıkları ve Klinik Mikrobiyoloji
Benli, A., Özdemir, Y., Özmen, C., Demirci, M., Gezer, Y., YILDIRIM, D. Y., Geyiktepe-Güçlü, C., Güçlü, K. G., Borcak, D., & Yörük, G. (2024) · Akademisyen Kitabevi eBooks · doi:10.37609/akya.3316
Jak leczyć zakażenia wywołane przez bakterie wielolekooporne?
Konopka, A. (2024) · Folia Cardiologica · doi:10.5603/fc.97423
New Therapeutic Strategies Against Carbapenem-Resistant Gram-negative Bacteria
(2024) · Frontiers research topics · doi:10.3389/978-2-8325-5709-9
Ambulatory parenteral antibiotic therapy in urology: innovations and perspectives
Štefan, M. (2024) · Urologie pro praxi · doi:10.36290/uro.2024.073
Antibiotic-Resistant Pathogens in Ear, Nose, and Throat Infections
Brook, I. (2024) · Springer eBooks · doi:10.1007/978-3-031-68449-4_2
莫, 双. (2024) · Advances in Clinical Medicine · doi:10.12677/acm.2024.14113028
Sánchez, M. F. G., González, P. I. B., Muicela, E. I. G., & Rojas-Lupercio, B. S. (2024) · Anatomía Digital · doi:10.33262/anatomiadigital.v7i4.1.3247
Suárez, L., Hidalgo, W., & Uribe, N. (2024) · Salud UIS · doi:10.18273/saluduis.56.e:24042
„Burden of Disease“ durch multiresistente Erreger: Keine Entspannung in Sicht!
Ambrosch, A. (2024) · Trillium Diagnostik · doi:10.47184/td.2024.04.05
Liu, X., Lu, J., Wang, Z., Li, Z., Jiang, G., Shen, T., Ma, J., & Zheng, S. (2024) · Surgical Infections · doi:10.1089/sur.2024.216
“21 Zhang et al. demonstrated substantial bactericidal effects of ceftazidime – avibactam alone or in combination with aztreonam against Klebsiella pneumoniae carbapenemase (KPC) or New Delhi metallo-b -lactamase (NDM) carbapenemase-producing Klebsiella pneumoniae in both in vitro and in vivo…”
Algethami, A. G., Melybari, M. M., Althomali, N., Alwuthaynani, S. M. M., Alharbi, T. A., Zarban, Y. H., Asiri, A., Alghitran, A. A., Dighriri, I. M., Alqahtani, D. G., et al. (2024) · Journal of Ecohumanism · doi:10.62754/joe.v3i8.5627
Alzayer, R., Thabit, A. K., Almohanna, H., AlMahasnah, R., Aljuzair, Z. H., Alyaqoub, S., Aljishi, Y., & AlBassam, H. J. (2024) · Saudi Journal of Clinical Pharmacy · doi:10.4103/sjcp.sjcp_32_24
Tuon, F. F., Zequinão, T., Morales, R., & Telles, J. P. (2025) · Infectious Diseases in Clinical Practice · doi:10.1097/ipc.0000000000001424
Role of co-trimoxazole in current medical practice
Rajni, E., Jorwal, A., Garg, V. K., & Sharma, R. (2024) · Indian Journal of Health Sciences and Biomedical Research (KLEU) · doi:10.4103/kleuhsj.kleuhsj_571_23
Xəstəxanadaxili infeksiyalar və antibiotiklərə davamlılıq
Heydərova, F., Həsənova, G., Ələkbərova, L., & Əmrahova, Ə. (2025) · SCIENTIFIC WORK · doi:10.36719/2663-4619/110/75-80
Significant Publications on Infectious Diseases Pharmacotherapy in 2023
Stabler, A. V., Huynh-Phan, R., Amin, K., Lin, K., Patel, S. U., Zaidan, N., Stramel, S., & Thomas, J. L. (2025) · Journal of Pharmacy Practice · doi:10.1177/08971900251318816 · Cited by 2
“57 59 Kaye et al. conducted a phase 3, multinational, randomized, active-controlled, non-inferiority trial from September 5, 2019, to July 26, 2021, across 59 sites and 16 countries.”
McIntosh-Morgan, V., Roye-Green, K. J., Mullings, J., Akpaka, P. E., & Thoms-Rodriguez, C.-A. (2025) · IntechOpen eBooks · doi:10.5772/intechopen.115305
Stenotrophomonas maltophilia Kaynaklı İnfeksiyonların Tedavisi: Geleneksel Bir Derleme
Yumrucu, F. G., Kara, E., Dizman, G. T., İnkaya, A. Ç., Demirkan, K., & Metan, G. (2025) · Flora the Journal of Infectious Diseases and Clinical Microbiology · doi:10.5578/flora.2025011336
“Bu nedenle, seftazidim/avibaktam ve aztreonam kombinasyo-nu, aztreonamın inaktivasyonunun önlenmesini ve S. maltophilia ’ya başarılı bir şekilde etki göster-mesini sağlamaktadır [29,38] .”
InfluentialLi, J., Liu, Z., Wang, H., Xia, Y., Hu, Y., Wang, H., Xia, F., & Zou, M. (2025) · Research Square · doi:10.21203/rs.3.rs-6201161/v1
Conde, M. I., Vila-Gallego, C., Urruchua, M. V., Aguirrezabal-Arredondo, A. V., Benéitez, O. L. F., Vidal‐García, M., Ruiz-Rodríguez, P., & Domínguez-Menéndez, J. A. (2025) · Farmacia Hospitalaria · doi:10.1016/j.farma.2025.03.008
Research Progress on the Treatment of Common Pathogenic Bacterial Infections in the Urinary System
包, 美. (2025) · Advances in Clinical Medicine · doi:10.12677/acm.2025.1541171
Adverse Drug Reaction Reporting of Beta-Lactam Antibiotics: A Focus on Cefoperazone-Sulbactam
Bibave, K. H., Sarak, A. B., Rone, A. S., & Sable, P. N. (2025) · International Journal of Advanced Research in Science Communication and Technology · doi:10.48175/ijarsct-25774
Conde, M. I., Vila-Gallego, C., Urruchua, M. V., Aguirrezabal-Arredondo, A. V., Benéitez, O. L. F., Vidal‐García, M., Ruiz-Rodríguez, P., & Domínguez-Menéndez, J. A. (2025) · Farmacia Hospitalaria · doi:10.1016/j.farma.2025.04.006
Mise au point sur le bon usage des fluoroquinolones – Actualisation 2025 de la SPILF et du GPIP
Vuotto, F., Bru, J. P., Canouï, É., Caséris, M., Chopin, M., Cohen, R., Diamantis, S., Dinh, A., Fillâtre, P., Gauzit, R., et al. (2025) · Médecine et Maladies Infectieuses Formation · doi:10.1016/j.mmifmc.2025.04.368
Nishiwaki, T., Yoshimura, S., Hosokawa, N., Matsui, H., Ashikawa, T., Funato, T., Nakaji, S., & Takahashi, H. (2025) · Digestive Diseases · doi:10.1159/000546606
“Based on the results of this study, in cases with antibiotic use within 90 days or EST, where CAE is suspected, carbapenems or cefepime should be considered as treatment options [4].”
Li, Y., Ye, J., Zhang, C., Gao, W., Zhang, H., Zheng, C., Feng, Z., Song, M., Hao, J., Zuo, H., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1599958
Unplanned Healthcare Encounters in Drug-Resistant Urinary Tract Infections in Emergency Departments
Brochu, J. M., Gunaga, S., Kenney, R. M., & Veve, M. P. (2025) · Cureus · doi:10.7759/cureus.85138
“However, plasmids that encode for ESBL enzymes often confer resistance to other antibiotic classes as well, including oral agents, which leaves intravenous (IV) carbapenems as preferred therapy [2].”
Nwosu-Izevbekhai, O. (2025) · Journal of Nursing Education and Practice · doi:10.63564/jnep.v15n6p62
“[3] She was prescribed ciprofloxacin (250 mg immediate-release tablets every 12 hours for three days), which temporarily resolved symptoms.”
Zaloszyc, A., Dratwa, M., & Verger, C. (2025) · Bulletin de la Dialyse à Domicile · doi:10.25796/bdd.v8i2.87071
Antibiograms in clinical practice
Kolář, M., Sedláková, M. H., & Bogdanová, K. (2025) · Vnitřní lékařství · doi:10.36290/vnl.2025.049
Availability of antimicrobials in a university hospital complex in southeastern Brazil
de Oliveira, G. A., & Reis, A. M. M. (2025) · Journal of Hospital Pharmacy and Health Services · doi:10.30968/jhphs.2025.162.1257
Giuliano, S., Piccirilli, A., Angelini, J., Patriarca, F. F., Fanin, R., Martini, L., Semenzin, T., Fanin, M., Lanini, S., Bonomo, R. A., et al. (2025) · JAC-Antimicrobial Resistance · doi:10.1093/jacamr/dlaf109
Self-citationA Practice Primer and Update on Anti-Bacterial Resistance.
Au, P. H., Gandhi, M. H., Deere, K., Patel, J., & Regunath, H. (2025) · PubMed Central
Nayab, A., Khan, S., Jahangir, A., Dhiloo, A. K., Saleem, Z., & Kashif, M. (2025) · Romanian Journal of Pharmaceutical Practice · doi:10.37897/rjphp.2025.1-2.3
Novel therapy for malignant otitis externa: A comprehensive review of garenoxacin therapy
Chowdary, K. K., & Paladugu, S. (2025) · Journal of Dr. YSR University of Health Sciences. · doi:10.4103/jdrntruhs.jdrntruhs_104_24
Arani, P. W., Pradana, F. J. P., & Sartika, R. D. (2025) · Pharmacy Education · doi:10.46542/pe.2025.252.103113
Xie, L., Wu, Y., Huang, Q., & Sun, J. (2025) · BMC Microbiology · doi:10.1186/s12866-025-04310-y
Pogue, J. M., & Kaye, K. S. (2025) · Clinical Infectious Diseases · doi:10.1093/cid/ciaf534
Vijayarani, G., Blessina Paulin, T., Sudha, K., Natarajan, S. V., Sasikala, G., & Usha, B. (2025) · International Journal of Research in Medical Sciences · doi:10.18203/2320-6012.ijrms20253140
Linh, N. K., Thao, B. T. H., Châu, T. M., & Hải, H. B. (2025) · Tạp chí Nghiên cứu Y học · doi:10.52852/tcncyh.v194i9.3895
Hemal, S., Sohana, R., Parveen, M. S., & Kumar, T. P. (2025) · Lecture notes in networks and systems · doi:10.1007/978-981-96-7508-1_15
Sánchez, D., de Michelena, P., Camacho, J., Belizón, B., Cano, S., Poirel, L., Colomina, J., Navarro, D., & Torres, I. (2025) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2025.117142
Zhang, H., Liang, B., Tan, Z., Wang, R., & Cai, Y. (2025) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkaf386
Lee, J. Y., Kim, Y. J., Kim, Y. J., Han, S. B., Suh, J., Lee, S. Y., & Kim, J. (2025) · Pathogens · doi:10.3390/pathogens14111103
“In addition, ESBL-producing Enterobacterales (ESBL-PEs) are often resistant to other classes of antibiotics beyond β -lactams [4].”
InfluentialWang, J., Tian, S., Li, J., Xu, L., Wang, P., Gu, G., Han, Y., Weng, Y., Zheng, T., Tao, Q., et al. (2025) · BMJ Open · doi:10.1136/bmjopen-2024-092219
“Bedside clinicians will immediately receive the results, and they will be suggested to adjust the anti-bacterial agents based on published guidelines 23–25 and available antimicrobial agents in China, as outlined in table 1.”
Jiang, H., Chen, Z., & Chen, D. (2025) · Future Microbiology · doi:10.1080/17460913.2025.2590882
Хатьков, И. Е., Drokov, M. Y., & Gasieva, O. Y. (2025) · Siberian Journal of Oncology · doi:10.21294/1814-4861-2025-24-5-96-106
Zela‐Coila, F., Vizcarra-Jiménez, S. F., & Taype-Rondán, Á. (2023) · Revista del Cuerpo Médico Hospital Nacional Almanzor Aguinaga Asenjo · doi:10.35434/rcmhnaaa.2023.163.1948
Ghareeb, A. M., Raafat, M. M., Bazan, N. S., & Samir, R. (2024) · Figshare · doi:10.6084/m9.figshare.26751095
Evolution of Multi-drug Resistant Urinary Tract Infections in Central California
Garsevanyan, S. (2023) · eScholarship (California Digital Library)
Feng, Q., He, W., Xu, Q., & Cheng, W. (2025) · Urolithiasis · doi:10.1007/s00240-025-01798-x
Lee, H.-J., Sung-Yeon, C., Lee, D., Park, C., Byun, J., Chun, H., & Kim, Y. R. (2025) · Polish Journal of Microbiology · doi:10.33073/pjm-2025-045
“The Infectious Diseases Society of America recommends traditional non-carbapenem β-lactams over carbapenems when MDR P. aeruginosa is susceptible to both (Tamma et al. 2023).”
InfluentialBacteremic versus Non-Bacteremic Urinary Tract Infections: Predictors of Poor Clinical Outcome
Polyzou, E., Tsoupra, S., Gavatha, M., Skintzi, K., Delastic, A., Livieratos, A., Niarou, V., Gogos, C. A., & Akinosoglou, K. (2026) · Romanian Journal of Internal Medicine · doi:10.2478/rjim-2025-0025
Study of therapeutic regimens used in Intensive Care Units for sepsis's treatment
ΤΡΙΑΝΤΑΦΥΛΛΟΥ, Α. (2025) · University of Thessaly Institutional Repository (University of Thessaly)
Huang, S., Kuang, H., Li, M., Li, J., Li, Z., & Chen, J. (2026) · Research Square · doi:10.21203/rs.3.rs-8247621/v1
Baalbaki, N., Mohsen, M., Hadidi, M. A., Yuan, L., Boyle, L. A., Sackey, J. D., & Salim, T. (2026) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2026.117300
Ökeer, M., Aydemir, Ş., & Eraç, B. (2026) · TURKISH JOURNAL OF MEDICAL SCIENCES · doi:10.55730/1300-0144.6165
Mourad, A., Lorenz, N., Patel, K. K., Patel, I., & Pattathan, M. (2026) · Cureus · doi:10.7759/cureus.103978
“This finding indicates a non-carbapenemase-mediated mechanism, as carbapenemase-producing strains often exhibit broader multidrug resistance that limits oral treatment options [3,9].”
Saqib, U., Ratlamwala, S., Kibe, N., Baig, M. R., Hajela, K., & Sharma, S. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1767981 · Cited by 1
“Current therapeutic approaches against Kp include new-generation b -lactam/ b -lactamase inhibitor combinations like ceftazidime-avibactam, meropenem-vaborbactam, and imipenem-relebactam, and ce fi derocol (108, 109).”
Restriction Evaluation of Appropriate Carbapenem Therapy (REACT): A Multisite Observational Study
Wells, D. A., Mcknight, M., Jaggar, J., Cleveland, K. O., & DeKerlegand, A. (2026) · Journal of Pharmacy Technology · doi:10.1177/87551225261422672
Harris, N., Mackowiak, A., Wrenn, R., Lee, H., Reed, A., Erkanli, A., Turner, N., Moehring, R. W., & Deri, C. R. (2026) · Microbiology Spectrum · doi:10.1128/spectrum.03475-25
Unidentified Risk Factor for Serratia Arthritis: Livestock
Akar, A. (2026) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0000000000005203
Appropriate empirical treatment of urinary tract infections
García, J. E. (2024) · e_Buah
Anjitha, C., & Sony, S. (2026) · Proceedings of the Indian National Science Academy · doi:10.1007/s43538-026-00726-w
Trương, T. P., Trần, T. T., Le, P. M., Nguyen, V. T., Tạ, T. K., Trần, T. T., Tran, C. T., Le, P. M. D., Nguyen, Q. T., & Nguyễn, T. N. P. (2026) · Infezioni in Medicina · doi:10.53854/liim-3401-6
Kaya, A., Akyol-Seyhan, D., Memetali, S. C., Yaşar, M., Vahabi, M. M., Başkol-Elik, D., Dirik, Ş., Şanlıdağ, G., Avşar, C. B., Demir-Görür, M., et al. (2026) · The Journal of Infection in Developing Countries · doi:10.3855/jidc.21257
Aguilar-Luis, D., Silva-Caso, W. G., Pérez‐Lazo, G., Morales-Castillo, L., Camps, M., Soto‐Febres, F., Aguilar-Luis, M. Á., Aquino-Ortega, R., & del Valle-Mendoza, J. (2026) · BMC Microbiology · doi:10.1186/s12866-026-04847-6
Ding, L., Wu, X., 谢强, Liu, L., Liang, B., Shen, S., Guo, Y., Chen, J., & Hu, F. (2026) · Microbiology Spectrum · doi:10.1128/spectrum.03257-25
Manejo Da Sepse E Choque Séptico: Atualizações Em Fluidoterapia, Vasopressores E Antibióticos
Wung, S. C. Y., CHANG, E. J., FRANCO, L. D. M., NASCIMENTO, D. D. G. D., BATISTA, A. M., GONÇALVES, R. M., SANTOS, F. D. C., OLIVEIRA, L. D. S., SOARES, G. B., VALENÇA, J. S. B. M., et al. (2026) · Editora Pasteur eBooks · doi:10.59290/4320121291
Ross, P., Caro, S., Caro, F., Román, J. C., Núñez, C., & García, P. (2025) · Revista chilena de infectología · doi:10.4067/s0716-10182025000500166
Saleem, M., Khan, M. S., Ahmad, I., Qattan, M. Y., & Alharbi, M. S. (2026) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-026-05224-w
“This increased death toll is firmly recorded in the data provided throughout the world, where CPO infections tend to lead to delayed effective care, restricted treatment of choice, and a disproportionate occurrence of severe sepsis and organ malfunction (Tamma et al. 2023; Chen et al. 2023).”
Manejo de las infecciones graves por bacterias gramnegativas multirresistentes en el enfermo crítico
Garnacho‐Montero, J., Adriaensens-Pérez, M., Aldabó-Pallás, T., Anaya-Carrión, N., Ojeda, D., Cantón‐Bulnes, M. L., PASCALE, G. D., Fernández-Delgado, E., Póvoa, P. M. S. R., Galleymore, P. R., et al. (2026) · Medicina Intensiva · doi:10.1016/j.medin.2026.502443
Xiong, H.-F., Zhang, Y., & Sun, L. (2026) · Transplant Infectious Disease · doi:10.1111/tid.70187
“In vitro studies and adult clinical trials have demonstrated potent activity and a favorable safety profile compared with polymyxins [ 8–10 ].”
Kyung Sook, C. H. O. I., & Choi, H. K. (2026) · Korean Journal of Clinical Laboratory Science · doi:10.15324/kjcls.2026.58.1.10
González, J. D. C., Álvarez, J., Matta, L., Martínez, E., Galindez, J. A. O., & Paredes-Amaya, C. C. (2026) · Canadian Journal of Infectious Diseases and Medical Microbiology · doi:10.1155/cjid/1177057
Kurtz, P., Peloso, P. F. D., Albuquerque, A. M., Antunes, B. B. D. P., Ramos, G. V., & Bozza, F. A. (2026) · Antibiotics · doi:10.3390/antibiotics15040382
“Standard antibiotics often fail against these pathogens, necessitating the use of novel agents or combination therapies, which underscore the critical need for advanced treatment options like ceftolozane/tazobactam [1,6–8].”
Bloodstream infections in immunocompromised adult patients
Figueroa, E. P., Bonilla, A., Anun, C. J. D., García, F. Y., Gonzalez, J. G. M., Fernández, P., Garzón, M. I., Medeot, M. F., Hernández, D. V., Cometto, M. A., et al. (2026) · Revista Argentina de Microbiología · doi:10.1016/j.ram.2026.100709
Meng, F., Pan, H., He, J., Chen, Y., Huang, Y., Zou, X., Pan, F., & Nong, C. (2026) · Advances in Bioscience and Biotechnology · doi:10.4236/abb.2026.174009
Kandasamy, G., Selvaraj, L., Orayj, K. M., Almanasef, M. A., Asiri, R., Alzaydani, A., Assiri, R. A., Srikanth, D., & Ravikumar, J. K. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1799975
“The high burden of MDR observed among these organisms in our cohort reflects a broader global trend of escalating resistance to β -lactams, fluoroquinolones, and carbapenems, particularly in healthcare-associated infections (4, 14).”
Lee, Y., Seong, J. E., Lee, J. A., Kim, J. H., Ahn, J. Y., Jeong, S. J., Choi, J. T., Yeom, J., & Ku, N. S. (2026) · Journal of Korean Medical Science · doi:10.3346/jkms.2026.41.e183
Elafari, M. A., Mamad, A., Bibat, M. A., Slaoui, A., Karmouni, T., Koutani, A., & Elkhader, K. (2026) · SAS Journal of Medicine · doi:10.36347/sasjm.2026.v12i04.014
Mills, J., Rogozin, E., Seok, H., & Marchaim, D. (2026) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2026.02.007
Mao, M., Li, K., Lin, C., Qiu, X., Zhang, Z., Ma, D., & Li, Q. (2026) · Frontiers in Microbiology · doi:10.3389/fmicb.2026.1806227
“With the growing prevalence of multidrug-resistant (MDR) bacteria, carbapenems serve as a final option for combating severe infections (Tamma et al., 2023; Mishra et al., 2025).”
Burad, J. (2026) · Infectious diseases · doi:10.5772/intechopen.1014261 · Cited by 1
Hoang, B. H., Nguyen, L. K., Dinh, S. T., Bui, T. H. T., Nguyen, T. T., & Nguyen, T. K. (2026) · Microbial Drug Resistance · doi:10.1177/10766294261448634
“Finally, participants must have had a speci fi c clinical indication for treatment with high-dose ampicillin – sulbactam combined with colistin, speci fi - cally for CRAB strains exhibiting a meropenem MIC > 8 l g/ mL 17,18 and a colistin MIC of 2 l g/mL.”
Sicheng, Y. U. A. N., Tan, Y., Wu, P., Du, X., Guo, G., Lu, L. I., Wang, H., Dou, L., & Guo, T. (2026) · Jundishapur Journal of Microbiology · doi:10.5812/jjm-167755
Collins, M. E., Fung, L., Brewer, T. F., & Yang, S. (2026) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-026-05536-y
Balasubramaniam, K., Boopathy, S., Chidambaram, Y., & Sivaraj, S. K. (2026) · Medical Journal of Dr D Y Patil Vidyapeeth · doi:10.4103/mjdrdypu.mjdrdypu_183_25
Prevalencia de gérmenes multi resistentes de una Unidad de Terapia Intensiva recién implementada
González, M. A. P. (2026) · Revista Científica de Salud "Ciensa" · doi:10.67123/v2n1o2
Metadata
- Authors
- Tamma, P. D., Aitken, S. L., Bonomo, R. A., Mathers, A. J., van Duin, D., & Clancy, C. J.
- Affiliations
- Johns Hopkins University (US)
- University of Michigan (US)
- University Hospitals of Cleveland (US)
- University of Virginia (US)
- Department of Medicine, University of North Carolina School of Medicine , Chapel Hill, North Carolina ,
- University of Pittsburgh (US)
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2023-07-18
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W4384665204
- Cited by
- 740
- References
- 697
- Citations by year
- 2026: 134 · 2025: 159 · 2024: 335 · 2023: 84
- FWCI
- 60.82
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Clinical Infectious Diseases (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Pfizer
- AstraZeneca
- Infectious Diseases Society of America
- Case Western Reserve University
- Medicines Company
- Melinta Therapeutics
- Entasis Therapeutics
- European Society of Clinical Microbiology and Infectious Diseases (ESCMID 2022)
- Universidade Federal do Rio Grande do Sul
- Shionogi
- Basilea Pharmaceutica
- Wockhardt
- National Institutes of Health
- Centers for Disease Control and Prevention
- Allergan
- Topics
- Health Sciences › Medicine › Microbiology (medical) › Antibiotic Resistance in Bacteria
- Health Sciences › Medicine › Infectious Diseases › Antibiotic Use and Resistance
- Health Sciences › Medicine › Microbiology (medical) › Infections and bacterial resistance
- Keywords
- antimicrobial resistance, gram-negative bacterial infection, extended-spectrum beta-lactamase, AmpC beta-lactamase, carbapenem-resistant Enterobacteriaceae, Pseudomonas aeruginosa, carbapenem-resistant Acinetobacter baumannii, Stenotrophomonas maltophilia, antimicrobial therapy, empirical treatment, oral therapy, treatment duration, pediatric infection
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.